CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-20 | Huang Jane CMO, Hematology | Sale | −1,000 | $87.00 | $87K | 1,100 |
| 2017-11-16 | Huang Jane CMO, Hematology | Sale | −600 | $85.00 | $51K | 2,100 |
| 2017-11-15 | OYLER JOHN Chief Executive Officer | Sale | −3,798 | $79.16 | $301K | 411,313 |
| 2017-11-15 | OYLER JOHN Chief Executive Officer | Sale | −62,170 | $80.29 | $5.0M | 349,143 |
| 2017-11-15 | OYLER JOHN Chief Executive Officer | Sale | −100 | $80.84 | $8K | 349,043 |
| 2017-11-14 | OYLER JOHN Chief Executive Officer | Sale | −39,328 | $79.55 | $3.1M | 435,618 |
| 2017-11-14 | OYLER JOHN Chief Executive Officer | Sale | −20,407 | $80.10 | $1.6M | 415,211 |
| 2017-11-14 | OYLER JOHN Chief Executive Officer | Sale | −100 | $81.00 | $8K | 415,111 |
| 2017-11-13 | OYLER JOHN Chief Executive Officer | Sale | −8,109 | $82.67 | $670K | 491,891 |
| 2017-11-13 | OYLER JOHN Chief Executive Officer | Sale | −16,845 | $83.24 | $1.4M | 475,046 |
| 2017-11-13 | OYLER JOHN Chief Executive Officer | Sale | −100 | $84.04 | $8K | 474,946 |
| 2017-11-13 | Peterson Amy C. CMO, Immuno-oncology | Sale | −2,400 | $82.79 | $199K | 1,201 |
| 2017-11-13 | Peterson Amy C. CMO, Immuno-oncology | Sale | −1,201 | $83.31 | $100K | 0 |
| 2017-10-13 | BAKER BROS. ADVISORS LP Director | Other disposition | −49,200 | 0 | ||
| 2017-10-13 | BAKER BROS. ADVISORS LP Director | Other acquisition | +7,102 | 7,102 | ||
| 2017-10-13 | BAKER BROS. ADVISORS LP Director | Other acquisition | +7,102 | 7,102 | ||
| 2017-09-27 | OYLER JOHN Chief Executive Officer | Grant or award | +515,000 | 21,745,525 | ||
| 2017-09-27 | OYLER JOHN Chief Executive Officer | Grant or award · Share Option (Right to Buy) | +935,000 | 935,000 | ||
| 2017-09-27 | Wang Xiaodong Director | Grant or award | +410,000 | 12,935,393 | ||
| 2017-09-27 | Wang Xiaodong Director | Grant or award · Share Option (Right to Buy) | +750,000 | 750,000 |
Page 116 of 123 · 2,455 trades